-
Something wrong with this record ?
Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations
M. Hajkova, B. Hermankova, E. Javorkova, P. Bohacova, A. Zajicova, V. Holan, M. Krulova,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Lymphocyte Activation drug effects immunology MeSH
- Cyclosporine pharmacology MeSH
- Cytokines metabolism MeSH
- Dexamethasone pharmacology MeSH
- Glucocorticoids pharmacology MeSH
- Immunosuppressive Agents pharmacology MeSH
- Coculture Techniques MeSH
- Cells, Cultured MeSH
- Mycophenolic Acid pharmacology MeSH
- Mesenchymal Stem Cells cytology immunology metabolism MeSH
- Mice, Inbred BALB C MeSH
- Prednisone pharmacology MeSH
- Cell Proliferation drug effects MeSH
- Flow Cytometry MeSH
- Sirolimus pharmacology MeSH
- T-Lymphocyte Subsets cytology drug effects immunology MeSH
- Mesenchymal Stem Cell Transplantation methods MeSH
- Cell Survival drug effects MeSH
- Animals MeSH
- Check Tag
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Immunosuppressive drugs are widely used to treat undesirable immune reaction, however their clinical use is often limited by harmful side effects. The combined application of immunosuppressive agents with mesenchymal stem cells (MSCs) offers a promising alternative approach that enables the reduction of immunosuppressive agent doses and simultaneously maintains or improves the outcome of therapy. The present study aimed to determinate the effects of immunosuppressants on individual T cell subpopulations and to investigate the efficacy of MSC-based treatment combined with immunosuppressive drugs. We tested the effect of five widely used immunosuppressants with different action mechanisms: cyclosporine A, mycophenolate mofetil, rapamycin, and two glucocorticoids - prednisone and dexamethasone in combination with MSCs on mouse CD4+ and CD8+ lymphocyte viability and activation, Th17 (RORγt+), Th1 (T-bet+), Th2 (GATA-3+) and Treg (Foxp3+) cell proportion and on the production of corresponding key cytokines (IL-17, IFNγ, IL-4 and IL-10). We showed that MSCs modulate the actions of immunosuppressants and in combination with immunosuppressive drugs display distinct effect on cell activation and balance among different T lymphocytes subpopulations and exert a suppressive effect on proinflammatory T cell subsets while promoting the functions of anti-inflammatory Treg lymphocytes. The results indicated that MSC-based therapy could be a powerful strategy to attenuate the negative effects of immunosuppressive drugs on the immune system.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016906
- 003
- CZ-PrNML
- 005
- 20180518142005.0
- 007
- ta
- 008
- 180515s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12015-016-9703-3 $2 doi
- 035 __
- $a (PubMed)27866327
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hajkova, Michaela $u Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 12843, Prague 2, Czech Republic. Department of Transplantation Immunology, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic.
- 245 10
- $a Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations / $c M. Hajkova, B. Hermankova, E. Javorkova, P. Bohacova, A. Zajicova, V. Holan, M. Krulova,
- 520 9_
- $a Immunosuppressive drugs are widely used to treat undesirable immune reaction, however their clinical use is often limited by harmful side effects. The combined application of immunosuppressive agents with mesenchymal stem cells (MSCs) offers a promising alternative approach that enables the reduction of immunosuppressive agent doses and simultaneously maintains or improves the outcome of therapy. The present study aimed to determinate the effects of immunosuppressants on individual T cell subpopulations and to investigate the efficacy of MSC-based treatment combined with immunosuppressive drugs. We tested the effect of five widely used immunosuppressants with different action mechanisms: cyclosporine A, mycophenolate mofetil, rapamycin, and two glucocorticoids - prednisone and dexamethasone in combination with MSCs on mouse CD4+ and CD8+ lymphocyte viability and activation, Th17 (RORγt+), Th1 (T-bet+), Th2 (GATA-3+) and Treg (Foxp3+) cell proportion and on the production of corresponding key cytokines (IL-17, IFNγ, IL-4 and IL-10). We showed that MSCs modulate the actions of immunosuppressants and in combination with immunosuppressive drugs display distinct effect on cell activation and balance among different T lymphocytes subpopulations and exert a suppressive effect on proinflammatory T cell subsets while promoting the functions of anti-inflammatory Treg lymphocytes. The results indicated that MSC-based therapy could be a powerful strategy to attenuate the negative effects of immunosuppressive drugs on the immune system.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a kokultivační techniky $7 D018920
- 650 _2
- $a cyklosporin $x farmakologie $7 D016572
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a dexamethason $x farmakologie $7 D003907
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a glukokortikoidy $x farmakologie $7 D005938
- 650 _2
- $a imunosupresiva $x farmakologie $7 D007166
- 650 _2
- $a aktivace lymfocytů $x účinky léků $x imunologie $7 D008213
- 650 _2
- $a transplantace mezenchymálních kmenových buněk $x metody $7 D045164
- 650 _2
- $a mezenchymální kmenové buňky $x cytologie $x imunologie $x metabolismus $7 D059630
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a kyselina mykofenolová $x farmakologie $7 D009173
- 650 _2
- $a prednison $x farmakologie $7 D011241
- 650 _2
- $a sirolimus $x farmakologie $7 D020123
- 650 _2
- $a T-lymfocyty - podskupiny $x cytologie $x účinky léků $x imunologie $7 D016176
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hermankova, Barbora $u Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 12843, Prague 2, Czech Republic. Department of Transplantation Immunology, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic.
- 700 1_
- $a Javorkova, Eliska $u Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 12843, Prague 2, Czech Republic. Department of Transplantation Immunology, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic.
- 700 1_
- $a Bohacova, Pavla $u Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 12843, Prague 2, Czech Republic. Department of Transplantation Immunology, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic.
- 700 1_
- $a Zajicova, Alena $u Department of Transplantation Immunology, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic.
- 700 1_
- $a Holan, Vladimir $u Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 12843, Prague 2, Czech Republic. Department of Transplantation Immunology, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic.
- 700 1_
- $a Krulova, Magdalena $u Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 12843, Prague 2, Czech Republic. magdalena.krulova@natur.cuni.cz. Department of Transplantation Immunology, Institute of Experimental Medicine, Czech Academy of Sciences, Videnska 1083, 14220, Prague 4, Czech Republic. magdalena.krulova@natur.cuni.cz.
- 773 0_
- $w MED00184570 $t Stem cell reviews $x 1558-6804 $g Roč. 13, č. 1 (2017), s. 104-115
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27866327 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180518142143 $b ABA008
- 999 __
- $a ok $b bmc $g 1300530 $s 1013746
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 13 $c 1 $d 104-115 $i 1558-6804 $m Stem cell reviews $n Stem cell rev. $x MED00184570
- LZP __
- $a Pubmed-20180515